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PRÉCIS 
Worldwide research and development expenditures on an HIV vaccine are 
approximately one billion U.S. dollars per year. While vaccines have been 
highly successful in preventing diseases, the most promising clinical trials to 
date suggest that a vaccine for HIV will be only moderately efficacious in 
preventing infection and will require multiple doses. We explore the ethical 
and policy implications of a moderately effective HIV vaccine. We examine 
anticipated costs, benefits, risks, and dissemination challenges. We conclude 
that a twofold approach of (1) using existing treatments to reduce viral loads 
and prevent transmission and (2) pursuing a cure for HIV may be more cost-
effective and beneficial in the long run than developing a vaccine. 
I.  INTRODUCTION 
More than three decades have passed since the initial clinical observation 
of Acquired Immunodeficiency Syndrome (AIDS) cases in 1981 and since the 
discovery of the etiologic agent, Human Immunodeficiency Virus (HIV) in 
1983.1 Since these discoveries, public, philanthropic, and commercial entities 
have invested in research to discover how to prevent, treat, and cure HIV and 
AIDS. Through this research, great advances have been made, most 
importantly, the discovery of Combination Antiretroviral Therapy (cART), 
which has converted AIDS from a nearly universally fatal disease to a chronic 
condition.2 Significant research has been made in prevention as well, 
including: antiretroviral treatments to prevent transmission,3 pre-exposure and 
post-exposure prophylaxis,4 education and prevention strategies,5 and methods 
to prevent the maternal-fetal transmission of HIV.6 
 
 1. Françoise Barré-Sinoussi et al., Past, Present and Future: 30 Years of HIV Research, 11 
NAT. REVS. MICROBIOLOGY 877, 877 (2013). 
 2. Id. at 879. 
 3. Myron S. Cohen et al., Prevention of HIV-1 Infection with Early Antiretroviral Therapy, 
365 NEW ENG. J. MED. 493, 494 (2011). 
 4. See Kenneth H. Mayer, Antiretroviral Chemoprophylaxis: State of Evidence and the 
Research Agenda, 59 CLINICAL INFECTIOUS DISEASES S47, S47 (Supp. 2014); Dawn K. Smith et 
al., Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other 
Nonoccupational Exposure to HIV in the United States: Recommendations from the U.S. 
Department of Health And Human Services, MORBIDITY & MORTALITY WKLY. REP., 
RECOMMENDATIONS & REPS., Jan 21, 2005, at 1, 3. 
 5. See Helen B. Chin et al., The Effectiveness of Group-Based Comprehensive Risk-
Reduction and Abstinence Education Interventions to Prevent or Reduce the Risk of Adolescent 
Pregnancy, Human Immunodeficiency Virus, and Sexually Transmitted Infections: Two 
Systematic Reviews for the Guide to Community Preventive Services, 42 AM. J. PREV. MED. 272, 
274 (2012). 
 6. See Kevin M. De Cock et al., Prevention of Mother-to-Child HIV Transmission in 
Resource-Poor Countries: Translating Research Into Policy and Practice, 283 JAMA 1175 
(2000). 
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None of these advances, however, promise to eradicate the virus from the 
population. To the extent that we have successfully eradicated other viruses—
such as polio and measles—it has been through the development and 
dissemination of vaccines. In general, such vaccines have been safe, effective, 
and cost-saving.7 Consider the vaccine for the Hepatitis B virus (HBV), a 
sometimes fatal virus that is transmitted in many of the same ways as HIV 
(through sexual intercourse and intravenous (IV) drug use).8 Five vaccines now 
exist.9 Each is approximately ninety-four percent effective in preventing 
chronic carriage of all known subtypes or variants of the virus.10 After 
vaccinating more than 100 million people in the U.S., no serious side effects 
have been reported.11 Only two to four doses are required in infancy to provide 
immunity throughout the first decade of life.12 With little public controversy, 
the vaccine has been mandated for infants in forty-seven states,13 and since 
1990, rates of acute Hepatitis have dropped eight-two percent.14 
Publicly promoting such a vaccine through coverage by the Affordable 
Care Act (ACA)15 and state mandatory vaccination laws arguably meets the 
five “justificatory conditions” proposed by James Childress and colleagues for 
justifying a public health policy, even when it clashes with some competing 
values: 
  (1) Effectiveness: The policy must be expected to achieve its aim (e.g., 
significantly reducing rates of HBV-infection was realistic through mandated 
vaccinations). 
 
 7. F. E. Andre et al., Vaccination Greatly Reduces Disease, Disability, Death and Inequity 
Worldwide, 86 BULL. WORLD HEALTH ORG. 140–42 (2008). 
 8. CTRS. FOR DISEASE CONTROL & PREVENTION, EPIDEMIOLOGY AND PREVENTION OF 
VACCINE-PREVENTABLE DISEASES 120 (William Atkinson et al. eds., 12th ed. 2012) [hereinafter 
VACCINE-PREVENTABLE DISEASES]. 
 9. Hepatitis B, NAT’L VACCINE INFO. CTR, http://www.nvic.org/Vaccines-and-Diseases/ 
Hepatitis-B.aspx (last visited Mar. 9, 2015); VACCINE-PREVENTABLE DISEASES, supra note 8, at 
124, xii. 
 10. VACCINE-PREVENTABLE DISEASES, supra note 8, at 134. 
 11. Hepatitis B FAQs for the Public, CTRS. FOR DISEASE CONTROL & PREVENTION, 
http://www.cdc.gov/hepatitis/B/bFAQ.htm, (last updated Mar. 6, 2015). 
 12. See VACCINE-PREVENTABLE DISEASES, supra note 8, at 126; Hepatitis B FAQs for 
Health Professionals, CTRS. FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/hepati 
tis/HBV/HBVfaq.htm (last updated Mar. 6, 2015). 
 13. State Mandates on Immunization and Vaccine—Preventable Diseases: Hepatitis B, 
IMMUNIZATION ACTION COALITION, http://www.immunize.org/laws/hepb.asp (last updated Jan. 
15, 2015) (listing Alabama, Montana and South Dakota as the three states who do not have a 
Hepatitis B childhood vaccination mandate.). 
 14. Incidence of Acute Hepatitis B—United States, 1990-2002, 52 MORBIDITY & 
MORTALITY WKLY. REP.1245, 1253 (2004). 
 15. See The Affordable Care Act and Immunization, DEP’T OF HEALTH & HUMAN SERVS., 
http://www.hhs.gov/healthcare/facts/factsheets/2010/09/The-Affordable-Care-Act-and-Immuniza 
tion.html (last updated Jan. 20, 2012). 
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  (2) Proportionality: The good achieved must balance favorably against the 
infringement of other values (e.g., reducing chronic HBV-infection rates by 
eighty-two percent helps to justify some degree of infringement on parental 
authority or diversion of funding for other health needs). 
  (3) Necessity: The infringement of a value such as autonomy must be 
necessary to achieve a public health aim such as herd immunity to Hepatitis B 
(e.g., current high rates of Hepatitis B vaccination arguably would have been 
difficult to achieve through a voluntary program). 
  (4) Least infringement: The infringement of other values should be 
minimized (e.g., children are not forcibly vaccinated, rather it is a condition for 
access to some school systems). 
  (5) Public justification: Policy makers should be transparent and explain 
the reasons for the policy (e.g., the Centers for Disease Control and Prevention 
(CDC) has developed an extensive website that provides information about 
Hepatitis B and the vaccination program).16 
The National Institute of Allergy and Infectious Diseases (NIAID) states 
that, “[f]inding a safe, effective, and durable HIV vaccine remains a top 
priority for NIAID.”17 Several HIV vaccines have advanced to human clinical 
trials in and have demonstrated some level of success in reducing infection 
rates.18 However, as we indicate in this paper, it appears that initial vaccines 
for HIV will be less effective, will require more doses to achieve immunity, 
will offer immunity for shorter periods of time, and accordingly, will be more 
expensive and difficult to administer than the Hepatitis B vaccine (or measles, 
polio, Human Papillomavirus (HPV), or any other commonly mandated 
vaccine.)19 The medical, economic, logistical, and political realities of HIV 
vaccines are extremely complex. This complexity generates a host of ethical 
and policy questions. 
This paper proceeds by identifying these questions, elucidating why they 
arise, and explaining their significance. As a general rule, we do not venture to 
answer these questions. In some instances, this is because further data is 
needed before anyone can answer the questions; in other instances, it is 
because the questions pertain to matters of policy that should be resolved 
through processes of public education, engagement, deliberation, and decision-
making. Simply outlining ethical and policy issues surrounding an HIV 
 
 16. James F. Childress et al., Public Health Ethics: Mapping the Terrain, 30 J. L. MED. & 
ETHICS 170, 173 (2002). 
 17. HIV Vaccine Research, NAT’L INST. OF ALLERGY & INFECTIOUS DISEASES (last updated 
Feb. 19, 2014), http://www.niaid.nih.gov/topics/hivaids/research/vaccines/Pages/default.aspx. 
 18. See, e.g., An HIV Vaccine: The World’s Best Long-Term Hope for Ending AIDS, FRED 
HUTCHINSON CANCER RES. CTR., http://www.hvtn.org/en.html (last visited Mar. 25, 2015); 
Mattia Bonsignori et al., An Autoreactive Antibody From an SLE/HIV-1 Individual Broadly 
Neutralizes HIV-1, 124 J. CLINICAL INVESTIGATION 1835, 1835 (2014). 
 19. See infra Part III.A. 
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vaccine may sound like a modest goal, but we believe it is crucial at this 
juncture. 
Perhaps no other disease has generated so many passionate stakeholder 
groups, including: 
 Those at highest risk within the U.S., including men who have sex with 
men (MSM) and IV drug users (IVDU), who have often been 
marginalized in society; 
 Those at highest risk internationally, including heterosexual men and 
women in many African nations; 
 Children who are orphaned by AIDS; 
 Government officials who seek to fight HIV/AIDS while wrestling with 
budget constraints; 
 Health care providers who struggle with limits imposed by the scarcity 
of health resources; 
 Pharmaceutical companies that could advance their mission and generate 
profit with a vaccine discovery, but might also lose revenue from 
medications used to treat a chronic condition; and, 
 Public health experts who have had mixed success in behavior-based 
prevention efforts. 
In such a context, deliberations about HIV vaccines may be highly 
politicized and contaminated by rhetoric that could unduly influence decision-
makers if they are not well informed. This article is intended to provide 
stakeholders and policymakers with an overview of the complex issues 
surrounding an HIV vaccine and a basic understanding of why the complexity 
will resist easy solutions. 
While HIV has affected many nations more severely than the U.S. (e.g., in 
sub-Saharan Africa almost one in twenty adults is infected),20 we focus our 
analysis on the U.S. context to examine more effectively, questions 
surrounding approval from the Food and Drug Administration (FDA), patent 
law, social dynamics, and other questions that are nation-specific. 
In Part II, we provide a description of HIV—or more accurately, the types, 
groups, and genetic subtypes of retroviruses in the HIV-family, the nature of 
HIV transmission, and the demographics of the disease burden. In Part III, we 
examine why it has been so difficult to develop an HIV vaccine, and we 
explore what kind of efficacy we can reasonably expect from the first 
generation of HIV vaccines. In Part IV, we try to anticipate the risks of an HIV 
vaccine, including adverse events, unintended changes in behavior, and social 
harms. In Part V, we discuss factors that will drive up the costs of an HIV 
vaccine and discuss some of the ethical issues presented by costs. In Part VI, 
we try to anticipate controversies surrounding the distribution of an HIV 
 
 20. HIV/AIDS Fact Sheet N°360, WORLD HEALTH ORG., http://www.who.int/mediacentre/ 
factsheets/fs360/en/ (last updated Nov. 2014). 
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vaccine. We conclude by applying the five justificatory conditions for public 
health policies and practices to an HIV vaccine. In the process of doing so, we 
hope not only to raise awareness of how challenging HIV vaccines are to 
public policy, but also to identify significant knowledge and process gaps that 
should be met prior to evaluating an HIV licensing application. 
II.  THE PROBLEM OF HIV 
HIV was first recognized in June of 1981, when the CDC reported five 
cases of pneumonia caused by Pneumocystis jirovecii (at that time referred to 
as Pneumocystis carinii) in MSM living in Los Angeles.21 These first cases 
were thought to be a new disease confined to the population of MSM, but it 
soon expanded to heterosexual men and women and IVDUs throughout much 
of the world.22 In 1983, a retrovirus (now known as HIV) was isolated from a 
patient with this syndrome in France.23 Within that same year, the FDA 
approved a commercial test to detect the virus.24 
HIV manifests as an acute infection with symptoms appearing two to six 
weeks after laboratory seroconversion.25 Symptoms include maculopapular 
rash, fever, myalgia, arthralgia, headache, diarrhea, sore throat, or neurological 
manifestations.26 Extremely high levels of the virus are present during acute 
infection and are likely a significant source of transmission.27 Antibodies to 
HIV normally develop within two months,28 although there have been sporadic 
reports of delayed seroconversion.29 For the most part, these antibodies are not 
able to control or prevent ongoing viral replication.30 
According to CDC criteria, AIDS is diagnosed when the immune system 
of a person infected with HIV becomes severely compromised (as measured by 
the CD4 cell count) and/or the person becomes ill with an opportunistic 
infection.31 Without HIV therapy, the individual becomes increasingly 
 
 21. First Report of AIDS, 50 MORBIDITY & MORTALITY WKLY. REP. 429, 429 (2001). 
 22. Barré-Sinoussi et al., supra note 1, at 877; Michael H. Merson et al., The History and 
Challenge of HIV Prevention, 372 LANCET 475, 475 (2008). 
 23. Barré-Sinoussi et al., supra note 1, at 877. 
 24. Id. 
 25. Andrew R. Moss & Peter Bacchetti, Natural History of HIV Infection, 3 AIDS 55, 55 
(1989). 
 26. Id. 
 27. Penny Lewthwaite & Ed Wilkins, Natural History of HIV/AIDS, 37 MED. 333, 333 
(2009). 
 28. Id. at 334. 
 29. Moss & Bacchetti, supra note 25, at 55; see also S. Skidmore et al., A Case Study of 
Delayed HIV-1 Seroconversion Highlights the Need for Combo Assays, 20 INT’L J. STD & AIDS 
205, 205 (2009). 
 30. Moss & Bacchetti, supra note 25, at 55. 
 31. About HIV/AIDS, CTRS. FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/ 
hiv/basics/whatishiv.html (last updated Jan. 16, 2015). 
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susceptible to opportunistic infections,32 and diseases caused by these 
pathogens are “AIDS-defining conditions,” and include herpes viruses 
(Kaposi’s sarcoma, lymphoma, and cytomegalovirus), Pneumocystis jerovicii, 
invasive fungal infections, and mycobacterial infections such as TB.33 In the 
absence of treatment, AIDS develops eight to ten years after initial infection.34 
When the first cases of AIDS presented to clinicians, the only thing they could 
do was treat the opportunistic infections with marginal success. HIV became 
the leading cause of death in twenty-five to forty-four year olds by 1993.35 
This trend peaked in 1996 before rapidly declining and, by 2010, HIV was the 
seventh leading cause of death in that age group.36 Today, with advances in 
cART, HIV has been transformed from a once fatal to a now manageable 
chronic disease.37 While current cART suppresses the virus, it does not 
eradicate it, and lifelong treatment is still required,38 which carries both 
financial and physical costs. A few cases of HIV eradication (cure) or 
suppression without requiring cART (functional cure) have been reported,39 
but have generally been in unusual circumstances, such as extremely early 
treatment,40 or a bone marrow transplant by a donor genetically incapable of 
HIV infection,41 and rebound has been reported in several of these cases.42 
 
 32. Id. 
 33. Revised Surveillance Case Definition for HIV infection Among Adults, Adolescents, and 
Children Aged < 18 Months and for HIV Infection and AIDS Among Children Aged 18 Months to 
< 13 Years – United States, 2008, 57 MORBIDITY & MORTALITY WKLY REP 1, 9 (2008) 
(outlining the AIDS-Defining Conditions in Appendix A). 
 34. Jair C. Leao et al., Oral Complications of HIV Disease, 64 CLINICS 459, 460 (2009). 
 35. Update: Mortality Attributable to HIV Infection Among Persons Aged 25-44 Years – 
United States 1994, 45 MORBIDITY & MORTALITY WKLY REP. 121, 121 (1996). 
 36. KAISER FAMILY FOUND., THE HIV/AIDS EPIDEMIC IN THE UNITED STATES 1 (2014) 
(citing to the CDC’s Mortality Slide Show Through 2010); CTRS. FOR DISEASE CONTROL & 
PREVENTION, MORTALITY SLIDE SERIES 20 (2013), available at http://www.cdc.gov/hiv/pdf/sta 
tistics_surveillance_HIV_mortality.pdf. 
 37. Barré-Sinoussi et al., supra note 1, at 879. 
 38. Id. at 880. 
 39. See generally Asier Sáez-Cirión et al., Post-Treatment HIV-1 Controllers with a Long-
Term Virological Remission After the Interruption of Early Initiated Antiretroviral Therapy 
ANRS VISCONTI Study, 9 PLOS PATHOGENE 1, 1 (2013). 
 40. Id.; Ari Bitnun et al., Early Initiation of Combination Antiretroviral Therapy in HIV-1 – 
Infected Newborns Can Achieve Sustainted Virologic Suppression With Low Frequency of CD4+ 
T Cells Carrying HIV in Peripheral Blood, 59 CLINICAL INFECTIOUS DISEASES 1012, 1014 
(2014). 
 41. Gero Hütter et al., Long-Term Control of HIV by CCR5 Delta32/Delta 32 Stem-Cell 
Transplantation, 360 NEW ENG. J. MED. 692, 696-97 (2009). 
 42. Press Release, Nat’l Inst. Of Allergy & Infectious Disease, “‘Mississippi Baby’ Now 
Has Detectable HIV, Researchers Find (Jul. 10, 2014), available at http://www.niaid.nih.gov/ 
news/newsreleases/2014/Pages/MississippiBabyHIV.aspx. 
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A. Viral Mechanisms of HIV 
HIV-1 and HIV-2 are members of the lentivirus family of retroviruses. 
Cross-species infection from primates to humans probably occurred by blood 
contamination through hunting. HIV-1 and HIV-2 both cause AIDS, but HIV-2 
is both less virulent and less prevalent.43  HIV-1 causes over ninety-eight 
percent of AIDS cases worldwide.44 “HIV-1 can be further subdivided into 
different groups (M, O, [N, and P]) and subtypes.”45 For example, HIV-1 
group M has nine identified genetic subtypes (A-K, excluding E and I).46 Each 
genetic subtype is traditionally associated with specific geographical areas. For 
example, subtype A is associated with West Africa, and subtype B is most 
prevalent in Europe, the Americas, Japan, Thailand, and Australia.47 “Globally, 
subtype C accounts for half of all strains.”48 It is likely that a vaccine will 
target only certain subtypes, complicating vaccine distribution. 
Retroviruses such as HIV have an RNA-genome and require reverse 
transcription to complete the viral life cycle.49 This process is inaccurate, and 
the viral genome is capable of mutating each base pair in its genome up to 
100,000 times per day, generating quasi-species of genetically-related viruses 
soon after infection.50 
B. Transmission Demographics 
HIV is present in blood, semen, and other bodily fluids and is transmitted 
mainly through sexual intercourse.51 Globally, the primary modes of 
transmission are heterosexual contact and mother to child (vertical 
transmission), but considerable variation exists between and within countries.52 
 
 43. Lewthwaite & Wilkins, supra note 27, at 333; Andrew M.L. Lever, HIV: The Virus, 37 
MED. 313, 313 (2009). 
 44. Lever, supra note 43, at 313. 
 45. Lewthwaite & Wilkins, supra note 27, at 333; Ana Vallari et al., Confirmation of 
Putative HIV-1 Group P in Cameroon, 85 J. VIROLOGY 1403, 1403 (2011). 
 46. Abraham J. Kandathil et al., Molecular Epidemiology of HIV, 121 INDIAN J. MED. RES. 
333, 334 (2005). 
 47. Id. at 337; Lewthwaite & Wilkins, supra note 27, at 333. 
 48. Lewthwaite & Wilkins, supra note 27, at 333. 
 49. Lever, supra note 43, at 313. 
 50. Ricardo Sobhie Diaz et al., Divergence of HIV-1 Quasispecies in an Epidemiologic 
Cluster, 11 AIDS 415, 415 (1997); Alan S. Perelson et al., HIV-1 Dynamics in Vivo: Virion 
Clearance Rate, Infected Cell Life-Span, and Viral Generation Time, 271 SCIENCE 1582, 1583 
(1996). 
 51. Lewthwaite & Wilkins, supra note 27, at 333. 
 52. Id. 
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The primary modes of transmission in the U.S. for example, are anal sex and 
IV-drug use.53 
We focus on demographic data provided in the CDC’s HIV Surveillance 
Report, 2012.54 Approximately 880,400 (or three in one thousand) individuals 
are known to be living with HIV throughout the U.S.55 The CDC estimates that 
approximately 200,000 additional individuals are infected, but are unaware of 
their infection.56 There are approximately 50,000 new diagnoses of HIV and 
20,000 deaths from HIV-related illnesses each year.57 The distribution of HIV 
varies significantly by race in the U.S. with Black/African American (forty-six 
percent), White (twenty-eight percent), and Hispanic/Latino (twenty-one 
percent).58 Among males, the primary modes of transmission are male-to-male 
sexual contact (eighty-one percent), followed by heterosexual contact (ten 
percent), and injection drug use (five percent).59 Among women, transmission 
occurs primarily through heterosexual contact (eighty-seven percent) and 
injection drug use (twelve percent).60 Children under thirteen comprise half of 
one percent of all cases, most involving peri-natal transmission (fifty-seven 
percent).61 
III.  THE DIFFICULTY OF DEVELOPING AN HIV VACCINE 
Vaccines have led to the eradication of smallpox and near eradication of 
polio, and protect humans from measles, rubella, tetanus, mumps, influenza, 
and Hepatitis B.62 Wayne Kopf provides a succinct explanation of different 
ways vaccines work: 
Viral vaccines protect against disease by priming the immune system before 
pathogen exposure. This generates antibody responses that can prevent 
infection [as well as] cellular responses that target and eliminate virus-infected 
cells. Virus-specific neutralizing antibodies bind to proteins on the surface of 
 
 53. CTRS. FOR DISEASE CONTROL & PREVENTION, TODAY’S HIV/AIDS EPIDEMIC 3 (2014), 
available at http://www.cdc.gov/nchhstp/newsroom/docs/HIVFactSheets/TodaysEpidemic-
508.pdf. 
 54. See generally Ctrs. for Disease Control & Prevention, Diagnoses of HIV Infection in the 
United States and Dependent Areas, 2012, HIV SURVEILLANCE REP., Nov. 2014 [hereinafter 
SURVEILLANCE REP.]. 
 55. Id. at 9. 
 56. Ctrs for Disease Control & Prevention, Monitoring Selected National Prevention and 
Care Objectives Using HIV Surveillance Data—United States and 6 Dependent Areas 2012, HIV 
SURVEILLANCE REP., Nov. 2014, at 1, 10 (Supp. Nov. 2014). 
 57. SURVEILLANCE REP., supra note 54, at 19, 40. 
 58. Id. at 18. 
 59. Id. 
 60. Id. at 19. 
 61. Id. 
 62. Ivan Stratov & Stephen Kent, Towards an HIV Vaccine, 32 AUSTRALASIAN SCIENCE 31, 
31 (2011). 
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viral particles and stop them from infecting host cells. Neutralizing antibodies 
can also bring about the destruction of virus-infected cells, via cellular effector 
mechanisms. Where natural virus infection elicits robust neutralizing-antibody 
responses, vaccines have been developed by using attenuated versions of the 
live virus (such as for measles, mumps, and rubella); inactivation (for polio); 
and virus surface protein subunits or virus-like particles (for hepatitis B and 
human papilloma virus).63 
Why, after more than three decades, do we not have an effective vaccine 
against HIV? Most importantly, currently available vaccines exist for 
pathogens to which many people develop protective immunity (i.e., patients 
who recover from the illness are protected against re-infection). The vaccine 
mimics this known protective response. Very few HIV-infected patients are 
able to control the infection and there are no patients identified who have 
cleared the infection completely. Those patients who do control the virus 
appear to do so by generating an effective cytotoxic T cell-response,64 which is 
quite different from the antibody-response generated by most licensed 
vaccines. 
Technical barriers exist as well. Because of safety concerns, an effective 
HIV vaccine would be unlikely to consist of attenuated, actively replicating 
(live) HIV, due to possible reversion to full virulence. Virus protein subunit 
vaccines or killed whole virus vaccines, have been problematic due to the 
extensive variability generated by the sloppiness of the viral polymerase, 
creating not a single target, but a swarm of related targets.65 This variability 
allows “the virus to escape both pharmacological attack and immunological 
defenses.”66 
Finally, scientists have never before attempted to develop a vaccine against 
a retrovirus like HIV. Retroviruses, by integrating their genome into ours, are 
able to hide completely from immune surveillance within quiescent 
lymphocytes.67 This means that any vaccine has a small window of opportunity 
in which to prevent infection and would have to be extremely effective, 
repelling all attempts by HIV to attach to and infect host cells. HIV produces 
viral proteins that actively interfere with the anti-HIV immune response in both 
infected and uninfected cells.68 For all these reasons, an effective HIV vaccine 
will likely require uniquely different strategies from currently licensed 
vaccines, which will likely increase cost and complicate distribution methods. 
 
 63. Wayne C. Koff, Accelerating HIV Vaccine Development, 464 NATURE 161, 161 (2010). 
 64. Stratov & Kent, supra note 62, at 32. 
 65. Dennis R. Burton et al., A Blueprint for HIV Vaccine Discovery, 12 CELL HOST & 
MICROBE 396, 396-97 (2012). 
 66. Lever, supra note 43, at 316; see also Travis C. Porco & Sally M. Blower, Designing 
HIV Vaccination Policies: Subtypes and Cross-Immunity, 28 INTERFACES 167, 167-68 (1998). 
 67. Lever, supra note 43, at 315. 
 68. Id. 
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Multiple vaccine strategies have been tried since the discovery that HIV 
causes AIDS. The first Phase I HIV vaccine trial took place in 1987.69 
According to the International AIDS Vaccine Initiative’s database, two 
hundred and twelve Phase I trials, nineteen Phase I/II trials, and thirty-four 
Phase II trials have taken place as of January 2015.70 These studies have 
provided both promising results and serious setbacks, most notably the early 
stopping of a Merck STEP vaccine study in 2003, after the realization that the 
vaccine increased the risk of HIV acquisition in some participants.71 Only three 
Phase III studies of HIV vaccines have been done, involving two AIDSVAX 
types (B/B in Canada, the Netherlands, and Puerto Rico; and B/E in 
Thailand)72 and a combination study of AIDSVAX B/E with ALVAC, also 
known as RV144.73 The most promising of these trials was RV144, a six-year 
trial conducted in Thailand with the sponsorship of the U.S. Army HIV 
Research Program and NIAID.74 The trial involved 16,400 people.75 While the 
vaccine had an initial efficacy of approximately seventy percent, this declined 
to about thirty percent within three and a half years.76 Although U.S. public 
health officials have never approved a vaccine with such low efficacy, the 
RV144 trial is the first vaccine to demonstrate any significant efficacy against 
HIV, and has renewed hopes for a marketable vaccine.77 
A. Anticipated Effectiveness of a Vaccine 
In evaluating the efficacy of a vaccine, several endpoints are used: (1) 
susceptibility to establishment of infection upon exposure, (2) progression of 
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 74. See RV 144 Trial, U.S. MILITARY HIV RES. PROG., http://www.hivresearch.org/research. 
php?ServiceID=13, (last visited March 9, 2015); see also Phase III Trial-Thailand, U.S. 
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Infection in Thailand, 361 NEW ENGL. J. OF MED. 2209, 2210 (2009). 
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VACCINE 6107, 6108 (2011). 
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the disease among those who are already infected, and (3) infectiousness or the 
risk of transmission to others. 
Most currently available vaccines are highly efficacious in reducing 
susceptibility to viral infection. For example, both vaccines currently licensed 
to prevent HPV—Gardasil and Cervarix—are nearly one hundred percent 
efficacious in preventing diseases caused by exposure to high-risk strains of 
HPV (HPV sixteen and eighteen),78 which together account for seventy percent 
of all cervical cancers as well as many cancers of the vagina and vulva.79 The 
HBV vaccine is ninety-four percent effective in preventing susceptibility to 
chronic carriage of the HBV.80 
In contrast to HPV and HBV vaccines, early HIV vaccines are likely to be 
low to moderate in reducing susceptibility, but may slow disease progression 
and lower infectiousness.81 Whereas efficacy in reducing susceptibility is the 
primary aim of vaccine development, control of the HIV epidemic could be 
achieved if a vaccine reduced the rate of transmission to less than one per 
infected individual.82 
In contrast to efficacy, which is determined under experimental conditions, 
effectiveness is the ability of a vaccine to produce outcomes of interest in the 
“real world” and is affected by factors such as patient compliance, cost, 
behavioral changes, and supply.83  However, when evaluating new drugs and 
biologics for safety and effectiveness, the FDA typically equates effectiveness 
with efficacy in clinical trials conducted under conditions that are often times 
more controlled than most patient care settings.84 
As we proceed to evaluate the risks and benefits of an HIV vaccine, we 
propose a hypothetical scenario. No HIV vaccine to date has exceeded an 
initial efficacy of seventy percent or sustained an efficacy above forty 
percent.85 We will optimistically, and somewhat arbitrarily, assume for the 
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sake of argument that a vaccine is sixty percent efficacious in preventing HIV 
upon exposure. However, it has a significantly lower rate of effectiveness 
because it requires recipients to obtain four shots over a six-month period as 
well as an annual booster shot.86 
B. Anticipating the Risks of an HIV Vaccine 
Proactive management of the risks of an HIV vaccine will be a necessary 
component of any successful HIV vaccine approval process and subsequent 
campaign. 
1. What adverse events might an HIV vaccine cause? 
HIV vaccine clinical trials have reported only mild to moderate vaccine 
reactions. Adverse events observed during HIV vaccine trials have been 
similar to other vaccines: pain and swelling localized at the injection site, 
fevers of mild to moderate severity, chills, diarrhea, aches and pains, nausea, 
headache, dizziness, and fatigue.87 Standard strategies for managing safety 
risks from vaccines include providing information on risks, adverse event 
reporting, long-term monitoring programs, and mechanisms of legal redress for 
injury.88 However, existing vaccine safety surveillance programs, such as the 
Vaccine Adverse Event Reporting System (VAERS), may be insufficient for 
adequately monitoring HIV vaccine safety, given the characteristics of likely 
recipient populations and the relative homogeneity of trial subjects. As 
VAERS relies on self-reporting and reporting by medical professionals,89 the 
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adverse events experienced in high-risk communities with limited health care 
access may go unreported. Moreover, it is unclear whether our standard 
processes for compensating those injured by vaccination will work with an 
HIV vaccine. Injuries attributed to most of the vaccines administered in the 
U.S., including the HPV and HBV vaccines, are compensated through the 
National Vaccine Injury Compensation Program (VICP).90 The VICP allows 
individuals claiming an injury caused by a covered vaccine to petition the U.S. 
Federal Claims Court for compensation, including coverage of the medical 
expenses incurred as a result of the injury.91 However, the VICP only covers 
vaccines that are routinely administered to children.92 Thus, an HIV vaccine 
would be added to the list of VICP covered vaccines only if it is recommended 
for routine administration to children. Moreover, a new mechanism for legal 
redress of HIV vaccine injuries will likely need to be developed. 
Additional concerns regarding vaccine safety could be addressed via FDA 
Risk Evaluation and Mitigation Strategies (REMS). A product of the Food and 
Drug Administration Amendments Act of 2007 (FDAAA),93 REMS are 
required risk management plans that extend beyond typical labeling 
requirements to ensure the benefits of a particular treatment outweigh its 
risks.94 The FDA is not required to order REMS for a particular biologic, but 
rather considers several factors in making that determination:  the size of the 
targeted population, seriousness of the disease, expected benefit and duration 
of the treatment, and the seriousness of potential side effects.95 Given the 
deadly and widespread nature of HIV, it seems the FDA could very well 
consider requiring REMS for an HIV vaccine. REMS must include a timetable 
for submissions of REMS-assessments and may also include a medication 
guide, a communication plan, elements to assure safe use, and an 
implementation system.96 Medication guides are written in non-technical 
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language and presented in an easily accessible format providing information 
such as possible side effects, overdose precautions and instructions, and a brief 
description of the product.97 Communication plans attempt to increase 
understanding of a drug’s or biologic’s risks through letters to health care 
providers, circulating information contained in the REMS to various 
professional societies, and encouraging methods to alleviate risks.98 Finally, 
Elements to Assure Safe Use (ETASU) establish the requirements that health 
care professionals must meet before administering, prescribing, or continuing a 
particular treatment.99 The related implementation system dictates the steps a 
drug or biologic sponsor will take to ensure that ETASU are executed and 
followed.100 Examples of ETASU include possessing specific training or 
certifications, or subjecting patients to monitoring.101 As a product of some or 
all of these parts, REMS can help identify and address concerns with vaccine 
safety. 
2. How will an HIV vaccine affect risky sexual behavior? 
As HIV prevention technologies diminish perceptions of risk, risk-taking 
behavior may increase, a phenomenon referred to as “risk compensation.”102 If 
individuals perceive a significant protective effect of an HIV vaccine, they 
may be more willing to engage in risky behaviors. Absent a fully protective 
vaccine and optimal uptake, increases in risky behavior, such as IVDU and 
unprotected sex, may increase the incidence of HIV transmission. For example, 
a decrease in the use of condoms, which provide between eighty and ninety 
percent protection against HIV when regularly used, may increase the overall 
incidence of HIV.103 Risk compensation thus has the potential to offset the 
population-level benefit of an HIV vaccine. In addition to diminishing the net 
benefit of an HIV vaccine, risk compensation may increase the incidence of 
other sexually transmitted infections, unwanted pregnancy, and IV use. 
Mathematical modeling suggests the extent to which risk compensation 
may offset the benefits of a vaccination program. However, mathematical 
modeling has been very limited. 
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Andersson et al. used prevalence data for South Africa to model the 
relationship between vaccine efficacy and risk compensation.104 Published in 
2007, the study concluded that a twenty-five percent decrease in condom use 
following a vaccination program, with a forty percent effective vaccine, would 
decrease HIV prevalence from twenty percent to fifteen percent (as compared 
to a decrease from twenty percent to thirteen percent without a decrease in 
condom use).105 The study assumed that the vaccine would have one hundred 
percent take (elicit some immunological response in all recipients), provide ten 
years of protection, and would be administered to seventy-five percent of the 
population over seventeen years of age.106 However, given a twenty percent 
effective vaccine and a fifty percent decrease in condom use, a vaccination 
program would increase the prevalence of HIV.107 As the model used the much 
higher prevalence rates found in South Africa (approximately eleven and a half 
percent for men; twenty percent for women),108 these findings do not provide 
an indication of how risk compensation might impact the benefits of a 
vaccination program in the U.S., which has very low prevalence rates. 
Long et al.’s discussion of the potential benefits and costs of an HIV 
vaccine considered how an increase in sexual partners would impact the 
benefits of vaccination.109 The authors concluded that if vaccinated individuals 
had twenty-five percent more sexual partners than unvaccinated individuals, a 
vaccine of at least sixty-five percent efficacy would provide a net benefit due 
to population mixing (HIV-infected individuals would be more likely to have 
sex with a vaccinated individual).110 The authors did not account for other 
changes in risk behavior. 
Blower et al.’s study of HIV eradication in San Francisco, which found 
that a modest increase in risk behavior of ten percent would offset any decrease 
in incidence offered by a fifty percent effective vaccine, offers the most insight 
into risk compensation following a vaccination program in the U.S.111 
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Subsequent work by Rajaraman et al. emphasizes the role of the 
transmission network in modulating the effectiveness of a vaccine 
intervention.112 In sexually transmitted diseases such as HIV, transmission 
requires risky behavior by both the infected patient and the uninfected 
partner—a two-sided behavior. This contrasts with diseases, such as influenza, 
that are primarily transmitted through the risky behavior of individuals. An 
individual’s risky behavior, including travel and contact with crowds, increases 
the risk of transmission to multiple others—a one-sided behavior.113 For one-
sided behaviors, high vaccination coverage mitigates increased risky behavior. 
For two-sided interactions, vaccination must be combined with programs to 
decrease risky behavior, as modeling of this behavior reveals that unintended 
outcomes occur at high levels of vaccination. Additionally, this modeling 
reveals that interventions that target highly connected individuals (as is 
common among HIV transmission networks) can sometimes be worse than 
random interventions.114 
Studies of anticipated behavioral changes have predicted a modest increase 
in risky behavior following vaccination with an HIV vaccine.115 In interviews 
conducted with 1,164 high-risk individuals in Los Angeles County, Newman et 
al. found modest anticipated increases in high-risk behaviors.116 After 
receiving a hypothetical HIV vaccine of fifty percent efficacy, six percent of 
respondents said they would use condoms less for vaginal sex, seven percent 
said they would use condoms less for anal sex, and approximately seven and a 
half percent anticipated an increase in sexual partners.117 However, anticipated 
risk compensation increased dramatically when subjects were presented with a 
high-efficacy HIV vaccine.118 Similarly, twenty-two percent of respondents in 
a South African study believed that they would use condoms less frequently 
after receiving a thirty percent effective vaccine.119 The conclusions supported 
by these studies are limited by the reliance on individual reporting of 
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anticipated changes in behavior, which may overestimate or underestimate 
actual changes in behavior. 
In contrast, studies of the behavioral changes of HIV vaccine trial 
participants suggest that risk compensation will not increase significantly in 
response to a vaccine.  A recent study of participants in a South African 
vaccine efficacy trial did not find evidence of risk compensation.120 The 
majority of trial participants maintained baseline risk behaviors during the 
course of the study. At six months, approximately thirty percent of men and 
thirty-six percent of women stated that they had changed from having 
unprotected sex to having protected sex.121 These findings are consistent with 
the observation that many participants in pre-exposure prophylaxis (PrEP) 
trials engaged in safer sexual practices after enrollment.122 
The decrease in risky sexual behaviors following enrollment in 
preventative trials may be attributed to the provision of risk counseling 
services.123 Preventative trials are designed to reduce potential harms and 
generally include a mechanism to minimize risk compensation. In addition to 
risk counseling, education regarding the efficacy of vaccines is crucial to 
minimizing risk compensation. The public is likely to overestimate the efficacy 
profile of an approved and marketed HIV vaccine. Interviews with high-risk 
individuals revealed that participants generally presumed that an approved 
vaccine would be one hundred percent efficacious.124 Moreover, an individual 
who has an all-or-nothing understanding of efficacy may increase risky 
behavior after HIV exposure, considering failure to contract the disease as 
evidence of a completely protective effect.125 
The extent to which informational initiatives may combat the problem of 
risk compensation is unclear. Participants who have reported engaging in risky 
sexual behavior during an HIV vaccine trial accurately recounted the trial’s 
directions to practice safe sex,126 suggesting that risk compensation is not 
solely attributable to information deficits. 
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Lessons may be learned from PrEP, a drug intervention that provides forty-
four percent additional protection against HIV infection.127 The CDC released 
guidance for PrEP in May 2014, recognizing that HIV preventative programs 
should be implemented in conjunction with other preventative services. 
According to the CDC, these include “educating patients about their 
medications; helping them anticipate and manage side effects; helping them 
establish dosing routines that mesh with their work and social schedules; 
providing reminder systems and tools; addressing financial, substance abuse, 
or mental health needs that may impede adherence; and facilitating social 
support.”128 The report acknowledges that current findings regarding that 
antiretroviral medication adherence may be only partially applicable to 
adherence enhancement among PrEP-users.129 
It is worth noting that despite good evidence for efficacy in multiple trials, 
there has been low uptake of PrEP thus far,130 indicating that there is still 
considerable confusion both among providers and patients about who should 
be prescribed PrEP, for how long, and how costs should be covered. However, 
physicians that work with the MSM community have said that a preventive 
measure that is available with more intermittent dosing might see more interest 
and uptake.131 Similar features might be present in a moderate-efficacy, high-
cost HIV vaccine. 
3. What social harms might an HIV vaccine cause for recipients? 
The social response to HIV/AIDS has historically been defined by social 
stigma and the threat of discrimination.132 An HIV vaccine may exacerbate 
existing stigmas and present new opportunities for discrimination, especially if 
the vaccine is disseminated to narrow populations already at risk of stigma and 
discrimination (such as the MSM community and racial minorities.)133 For 
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early recipients, the motivator for uptake may be perceived as engagement in 
high-risk behavior,134 potentially alienating the recipient from his or her 
community. Dissemination strategies must accordingly account for inadvertent 
privacy invasions through inference.135 For instance, mobile HIV vaccination 
sites may permit the inference that those entering or leaving are interested in 
receiving the vaccine because they engage in high-risk behaviors.136 Similarly, 
overutilization of needle exchange and HIV testing clinics as sources of 
vaccine dissemination may function to discourage uptake by associating 
recipients with high-risk behavior. 
In inducing an antibody-response, an HIV vaccine also induces 
seropositivity and thus, HIV vaccine recipients will test seropositive for 
HIV.137 Although false positives may be distinguished from actual viral 
seropositivity depending on the nature of the vaccine and the assay used, 
vaccine-induced seropositivity complicates the interpretation of HIV testing 
results, increasing the likelihood that an individual may be considered HIV 
positive.138 False seropositives mistaken for actual HIV infection may have 
implications for travel, immigration, and insurance discrimination.139 
C. Anticipated Costs 
At least two factors generate concern that the costs of an HIV vaccine 
could be too high to make global distribution feasible. First, Pharmaceutical 
Research and Manufacturers of America (PhRMA) estimates that research and 
development (R&D) of new drugs and therapeutics typically takes ten to 
fifteen years, costs an average of $1.2 billion, and only twenty percent of 
marketed drugs “return revenues that match or exceed R&D costs.”140 The 
total investment in R&D costs worldwide for an HIV vaccine from 2009-2013 
has been estimated at $4.27 billion (U.S.D.), which is sixty-eight percent of all 
investment in HIV/AIDS-R&D.141 In contrast, investment in prevention 
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treatment (ninety-six percent efficacious in preventing transmission) has been 
$0.24 billion (U.S.D.), or two percent of investment totals in the same time 
period.142 
A second potential financial barrier is the goal of generating significant 
income from sales to recoup R&D costs and generate a profit for investors, 
which might be both significant and protected by patent law. Simply defined, a 
patent is an exclusive property right granted to an entity for a particular 
invention so long as the invention is new or involving an inventive step; it is a 
right to exclude others from producing, using, or selling the patented 
invention.143 Patent law also grants patent holders with the authority to 
determine price setting within certain limits.144 Since patent holders are 
generally able to control price setting, subject to constraints on 
monopolization, the financial barriers to access can vary considerably.145 It is 
also important to note that any one vaccine contains several distinct parts or 
processes (e.g., antigen, adjuvant, and the delivery device), most of which are 
individually patentable.146 This feature of vaccination can make avoiding 
infringement difficult, as manufacturers must consider not only the vaccine 
itself, but the very basics of its composition.147 
One potential way of overcoming the obstacles to vaccine access in the 
U.S. is through compulsory licensing via antitrust laws and lawsuits for patent 
misuse.148 U.S. antitrust laws permit actions against a patent holder if the 
alleging party can demonstrate that a particular patent has been wrongfully 
broadened in a way that negatively affects either competition or the integrity of 
the patent system.149 If antitrust laws are breached, that patent can be deemed 
unenforceable or under certain circumstances the patent holder may be 
compelled to grant a third party a license to engage in the manufacture of the 
patented product.150 Another potential way to increase access in the U.S. is 
through the process of price negotiation. Since major health maintenance 
organizations (HMO) and pharmacy benefit managers cover sixty-seven 
percent of U.S. patients, this represents a particularly attractive mechanism for 
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driving down costs.151 Patent-pooling, a form of voluntary licensing, is another 
option licensors have to help increase manufacturing efficiency and reduce the 
costs of producing vaccinations.152 Patent-pooling is the process of joint 
licensors creating a pool of their respective patents so that one license can 
convey the entirety of the pool to a potential licensee.153 However, overusing 
voluntary licensing can have a negative impact on competition, as royalty 
payments typically do not lower prices to the same extent as general market 
competition. Lastly, the most common remedy for antitrust violations in the 
U.S. is the invocation of the government-use provision, 28 U.S.C. § 1498. This 
provision grants the government or its contractors the authority to use a 
patented product or process without license so long as the patent holder is paid 
“reasonable and entire compensation.”154 Determining an appropriate price 
would likely require consideration of the patented vaccine’s status under the 
Drug Price Competition and Patent Term Restoration Act (also known as the 
Hatch-Waxman Act), a major piece of legislation governing the approval and 
marketing of generic drugs.155 
A vaccine like the one proposed in this piece may also qualify for FDA-
granted market exclusivity for up to seven years if certain statutory 
requirements are met.156 By granting exclusivity, the FDA promotes innovation 
by rewarding manufacturers who expend the resources necessary to deliver 
new, effective products with exclusivity over the market, and thus, increase 
revenue. Moreover, this statutory exclusivity can exist without a concurrently 
running patent.157 This is another potential avenue available to help drive R&D 
while avoiding some of the hindrances of intellectual property and patent law. 
From an international standpoint, there are additional mechanisms within 
the Agreement on Trade Related Aspects of Intellectual Property (TRIPS) that 
serve to increase global access to important vaccines on a global level.158 
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TRIPS is the most comprehensive multilateral agreement on intellectual 
property. In addition to voluntary licensing and compulsory licensing 
mentioned above, TRIPS also includes two other measures: tiered pricing and 
bulk purchasing.159 Tiered pricing is the practice of setting prices based on the 
developmental status of the purchasing country.160 This approach, however, 
can be negatively affected by scheduled divergence, an event that hinders 
access because manufacturers cannot keep up with a vaccine demand that 
differs considerably between nations, especially when manufacturers rely on 
sales within developed countries to cover the majority of their costs.161 Lastly, 
TRIPS also provides for bulk purchasing and advanced purchasing 
commitments.162 The bulk purchasing mechanism operates on the general 
principle that a large volume of goods can be bought at a cheaper price per 
unit,163 a principle especially appropriate for vaccines, considering their 
widespread demand. Similarly, advanced purchase commitments (i.e., bulk 
purchasing done prior to development or widespread manufacturing) provide 
added incentives for developers and manufacturers to generate vaccines by 
assuring a willing purchaser.164 While patents may burden access to an 
approved HIV vaccine, there are existing mechanisms for overcoming these 
impediments. 
Even if the barriers of R&D costs and patent law are overcome and a 
reasonable price per dose is established, an HIV vaccine may still be cost 
prohibitive. Again for the sake of argument, we will stipulate a hypothetical 
cost per dose for each vaccine of $250 based on the analysis of Elisa Long and 
Douglas Owens.165 Based on our hypothesized dosing schedule of four doses 
in year one and an annual booster, the total cost is $1,000 in year one and the 
ten-year cost is $3,250 per person. If recipients do not follow up with the 
annual boosters, vaccine efficacy will decline rapidly.166 
Such costs may be prohibitive to widespread dissemination, particularly at 
a global level, where poverty is more prevalent and transmission patterns are 
not limited to easily identifiable high-risk groups. In fact, if an HIV vaccine is 
only moderately effective and some of its effectiveness is offset by behavioral 
risk adjustments, then the costs of an HIV vaccine do not supplant, but rather 
are added to the costs of other preventive measures and treatment. 
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D. Anticipated Distribution Controversies 
Distribution of an HIV vaccine will be affected by economic factors, 
logistics, the efficacy of the vaccine, and social reactions within different 
nations and communities. 
1. Should vaccine distribution target high-risk populations? 
For reasons of cost-effectiveness, a low to moderate efficacy HIV vaccine 
(less than eighty percent efficacy) will likely be recommended only for high-
risk populations.167 A low to moderate efficacy vaccine will also carry the 
same problems as the Bacille Calmette-Guérin (BCG) vaccination to prevent 
TB. For example, although it may be modestly effective, use of the BCG 
vaccine complicates health care services by interfering with the most 
commonly used testing modalities for asymptomatic (latent) TB.168 Similarly, a 
modestly effective HIV vaccine may be problematic, as it would result in 
positive HIV tests (i.e., ELISA and Western blot) for patients at highest risk 
for acquiring HIV. This would require the use of a more expensive test (the 
HIV viral load) for screening this population. 
It is unclear whether high-risk populations will spontaneously seek 
vaccination if the benefits are only modest. For example, even with good 
efficacy, when patients comply with a daily regime of PrEP, uptake has been 
very slow within the MSM community.169 It is likely that widespread 
vaccination within high-risk populations will require targeted vaccine 
campaigns, which may include social marketing, educational outreach 
programs, strategically located delivery centers, and financial incentivizing—
all of which add to the costs of a vaccine campaign.170 
While these strategies do not directly encroach upon the autonomy of the 
individual target recipient, they may compound social pressure and stigma. 
Social marketing, which exploits the desire for social acceptance, may 
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exaggerate perceptions of homogeneous characteristics (for example, the belief 
that all members of the MSM community practice unsafe sex) and exacerbate 
social anxieties among members of the target population.171 Educational 
outreach programs and local delivery centers may inadvertently facilitate 
perceptions that HIV is isolated to socially deviant communities. Financial 
incentives, when offered only to those in high-risk populations, may encourage 
perceptions of social dependency. Efforts to target vaccine uptake must 
balance public health goals with respect for target populations. 
The risk of alienating at-risk populations may be managed by including 
members of at-risk populations in the development of targeting campaigns. To 
minimize the risk of stigma and discrimination, targeting policies should also 
focus as much as possible on relevant individual factors, such as identifying 
populations with high prevalence of HIV in their sexual network, and 
individuals who present with recurrent sexually transmitted diseases (STD).172 
A focus on individually relevant factors rather than group generalizations will 
decrease opportunities for stigma. For example, targeting men who have 
unsafe sex with men, rather than the entire MSM community, recognizes the 
diversity of the MSM community.173 However, the tailoring of targeted 
vaccine policy to individual characteristics requires greater scrutiny, poses a 
risk of invading individual privacy, and would require physicians to take more 
complete sexual histories to identify individuals at risk.174 
The success of targeted vaccination efforts will be limited by inequalities 
in health care access, as dissemination programs will need to rely on the 
existing health care infrastructure.175 Thus, eradication of HIV will likely 
depend not only on the successful development of preventive technologies, but 
also investment in expanding the health care infrastructure to disadvantaged 
communities. For example, although African American and Latino 
communities have historically exhibited suboptimal uptake of vaccines and 
HIV treatment, poor uptake likely reflects access issues.176 
The Belmont Report, which provides ethical principles to guide research 
funded by the U.S. government, additionally raises justice-based concerns 
about targeting at-risk populations in the U.S. for distribution of a vaccine, if 
the clinical trials leading to the development and approval of a vaccine 
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recruited participants from developing nations.177 For example, individuals 
who assume the risks of clinical trials should belong to the same group of 
individuals who are likely to benefit from the trials.178 That is, the context of 
HIV vaccine research may require that we have a plan for affordable 
distribution of the vaccine within resource-poor nations concomitant with U.S. 
distribution. However, this will pose a significant challenge to the market if the 
vaccine is approved only for use in high-risk populations because this would 
radically restrict the size of the U.S. market, which commonly shoulders the 
primary burden in the recovery of R&D costs.179 
2. Might the state mandate an HIV vaccine? 
The question remains whether an approved HIV vaccine should be 
mandated. States have traditionally been charged with making determinations 
regarding mandatory vaccination via school attendance requirements as well as 
deciding which exemptions should be recognized.180 A state derives its 
authority to mandate vaccinations from the police power, a product of the 
Tenth Amendment to the U.S. Constitution, which grants states those powers 
“not delegated to the United States.”181 In Jacobson v. Massachusetts, the 
Supreme Court of the United States held that a Massachusetts law requiring 
citizens to undergo vaccination for smallpox was a valid exercise of the police 
power.182 The Court held that the law bore a substantial relationship to the 
protection of public health and it was reasonable for the state legislature to 
invest the Board of Health with the power to determine which diseases threaten 
the community’s safety.183 States also have traditionally relied on the parens 
patriae (Latin for “parent of the country”) doctrine, the traditional authority for 
the state to protect its citizens.184 
Since the states’ police power has been widely accepted for decades, 
primarily on the basis of public health, general vaccination requirements are 
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usually legitimate, subject to a few constitutional limits that vaccination laws 
must conform to in order to withstand constitutional scrutiny. First, the 
legislative measure must serve a public health necessity, which means the 
public health powers can only be invoked to combat an avoidable harm.185 
Second, the measure must be reasonable, namely it must bear a “real or 
substantial relation” to the protection of the public health.186 Third, the 
measure must be proportional, meaning the measure’s burden cannot be 
excessive or outweigh its anticipated benefit.187 Finally, the public health 
measure itself cannot cause harm to its subjects.188 So long as vaccination 
mandates conform to the above limitations, they will likely defeat 
constitutional challenges. 
States will need to keep in mind that just because an HIV vaccine is FDA-
approved does not mean that it will necessarily pass these four tests for the use 
of police powers. HIV vaccines with low, moderate, and high efficacy need to 
be treated differently. While a highly efficacious HIV vaccine could 
accomplish a public health benefit if mandated, a low or moderately 
efficacious HIV vaccine could very well have the opposite effect.189 Based on 
the fact that mandate decisions fall to the state, decisions of whether or not to 
mandate HIV vaccination will be geographical in nature and deeply influenced 
by a state’s rate of HIV infection. 
3. Social Controversy 
While the justification for mandating vaccination may be strongest in 
regard to diseases that spread by casual contact, there are other vaccinations 
commonly mandated even though their associated diseases are not likely to be 
spread via casual contact. For example, tetanus and Hepatitis B are unlikely to 
be contracted from casual contact, since tetanus is most commonly acquired 
through contamination of a cut or wound, and HBV is largely sexually-
transmitted.190 The highly infectious nature of HBV as a blood borne 
pathogen191 and the public health need to ensure the safety of the blood supply 
have likely also contributed to its inclusion as a mandatory vaccine. 
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Currently, HBV vaccination is mandatory in all states with the exceptions 
of Alabama, South Dakota, and Montana.192 It is interesting to contrast the 
history and status of the HBV vaccine to the HPV vaccine, which similarly 
aims to prevent the spread of a sexually transmitted virus. 
Over the past decade there has been notable protest regarding compulsory 
HPV vaccination of school-aged children.193 The controversy surrounding 
HPV vaccination is focused on both social and scientific grounds. From a 
scientific position, critics of mandatory vaccination feel that since the long-
term effectiveness of HPV vaccines is not known, it is inappropriate to 
mandate vaccination in light of uncertainties concerning risk to the public.194 
On the social side, critics of mandatory HPV vaccination focus on the fact that 
HPV is not casually contracted, although it is highly infectious, with a 
prevalence rate as high as fifty percent in sexually active female adolescents 
and young adults.195 These critics maintain that providing vaccinations for 
HPV may undermine abstinence-based teachings and that vaccines will offer a 
false sense of security that could lead to a decline in safe sex practices.196 
Vamos, McDermott, and Daley write: 
Childhood immunizations, such as measles, chicken pox, and polio, are 
mandatory for school-aged youth and are required because of their highly 
contagious nature, especially in settings where people congregate in large 
numbers. Therefore, the question is whether there is justification for mandating 
parents to vaccinate their children against a sexually transmitted virus, one that 
can only be transmitted through sexual behavior that some people view as 
being irresponsible.197 
Any effort to widely distribute an HIV vaccine may face similar challenges 
within certain sectors of society, which view sexual behavior not merely in 
terms of introducing “risk factors,” but also in terms of morality, and 
frequently, a traditional sexual morality that condemns sex outside of 
heterosexual marriage. 
Allowing exceptions to mandatory vaccination has been a means of 
addressing social outcry. Forty-eight states (excluding Mississippi and West 
Virginia) recognize religious exemptions.198 The level of evidence needed to 
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invoke a religious exemption varies by state. A few states require that the 
patient be a member of an organized, recognized, or established religion, while 
others grant exemptions only if the beliefs are “genuinely and sincerely held,” 
while still others require only a completed form stating opposition.199 
Philosophical exemptions are more malleable than their religious counterparts 
and are also more commonly invoked. Laws governing these exemptions 
typically require little evidence to support objection, many times only requiring 
a written statement.200 However, many states treat philosophical exemptions as 
an all or nothing affair, requiring one to forego all vaccinations instead of 
expressing objections to only specific vaccines.201 Twenty states recognize 
some form of philosophical exemptions.202 
Exceptions have not, however, always satisfied those who object to 
mandating vaccination. Following FDA approval of Gardasil and Cervarix and 
the recommendation of the national Advisory Committee on Immunization 
Practices (ACIP), state legislatures began drafting HPV vaccination laws.203 At 
least forty-two states have introduced HPV vaccination legislation to either 
require vaccination or provide funding to educate the public and twenty-five of 
these states have enacted such legislation with nearly all legislative measures 
focusing on grant-funding to educate the public.204 The road to specifically 
mandate HPV vaccinations has proven to be more difficult. Only Virginia and 
the District of Columbia currently have laws mandating HPV vaccination for 
schooling.205 
The 2007 events in Texas provide an illustrative example of challenges to 
mandatory vaccine laws covering STDs. In 2007, Texas Governor Rick Perry, 
believing immediate action was necessary, bypassed the state legislature and 
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issued an executive order mandating HPV vaccination for girls entering the 
sixth grade.206 Almost as quickly as its issuance, the newly signed law 
generated substantial public backlash.207 Even though the Texas law, like the 
Virginia and District of Columbia laws that are currently in force, allowed 
exemptions on medical, religious, and philosophical grounds, concerned 
parents still expressed disdain over the perceived erosion of their decision-
making authority and the hassle of having to formally request exemption.208 
Another common challenge confronting HPV vaccine mandates is the parental 
fear that vaccinating their children against a STD conveys an implied message 
that sexual activity before marriage is permissible.209 
Some opponents also argue that mandatory HPV vaccination laws violate 
the Equal Protection Clause of the Fourteenth Amendment as such laws 
(including both Virginia’s and the District of Columbia’s formulations) require 
only girls to be vaccinated despite the FDA’s approval for Gardasil usage 
among males.210 Following this extensive public backlash, the Texas 
legislature passed a bill nullifying Governor Perry’s executive order, and 
Governor Perry subsequently withheld his veto.211 Overall, the arguments 
advanced by Perry’s critics are the ones most commonly used to attack similar 
vaccination requirements and should be anticipated if an HIV vaccine is 
mandated. 
Interestingly, mandating vaccination for STDs has also proven 
controversial among some groups that support vaccination. For example, the 
Catholic Medical Association of the U.S. supports widespread HPV 
vaccination and identifies no ethical issues with the vaccine itself, but strongly 
opposes mandatory vaccination.212 We expect that if an HIV vaccine is not 
recommended for children, and if no attempts are made to mandate the 
vaccine, the backlash from religious groups will be significantly less than if the 
HIV vaccine was mandated for school-aged children. However, as a 
predominant STD, HIV vaccination is likely to be more effective if given prior 
to sexual debut. 
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Admittedly, mandatory HBV vaccination generated comparably little 
controversy and almost no literature, despite the fact that HBV is primarily 
sexually-transmitted.213 This may be due in part to the timing of the rollout of 
the HBV vaccine. The current vaccine has been used since 1986, a time in 
which there was considerable concern for the safety of the blood supply from a 
variety of blood borne pathogens, including HBV, HIV, and non-A/non-B 
Hepatitis (subsequently identified as Hepatitis C).214 We suspect that the 
increased controversy over HPV is due to backlash against vaccination from a 
younger population, which never experienced the original devastation caused 
by vaccine-preventable diseases, as well as increased influence from political 
factions within the U.S. that seek to minimize government intervention into the 
lives of citizens. In the current climate, mandating an HIV vaccine would 
likely receive a reaction more comparable to the HPV vaccine than to the HBV 
vaccine. Additionally, the potential backlash concerning mandatory HIV 
vaccination will likely be magnified based on its potential moderate efficacy 
profile as compared to the efficacy profiles of the HPV and HBV vaccines. 
IV.  CONCLUSION 
To summarize, based on the most promising clinical trials to date, we 
anticipate the first vaccine approved to prevent HIV infection will be only 
modestly effective. The type of HIV vaccine that can be expected will not fully 
eradicate the disease and, therefore, will not replace the need for ongoing and 
improved prevention and treatment efforts. Additionally, a broad vaccination 
campaign will be costly given that immunization may require multiple doses in 
the first year and annual booster doses. To avoid risk compensation, the 
vaccine campaign will require a significant educational component, though it is 
not clear that risk compensation is due to informational deficits. Social 
resistance to any effort at mandating an HIV vaccine is likely to be strong. 
While we have focused on the U.S. context, many of the overarching 
concerns—efficacy being limited to specific strains, costs, the burden of 
administering multiple doses, risk compensation, and social resistance—
pertain to international settings to an even greater extent than the U.S. 
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A. Suggestions for Justificatory Conditions 
We started this paper by presenting the ways that HBV vaccines arguably 
satisfy a set of widely recognized justificatory conditions for public health 
policies. In contrast to HBV vaccines, the HIV vaccines we anticipate in the 
near future do not satisfy the conditions nearly so well. However, in most 
cases, we lack the knowledge and clear processes to draw appropriate 
conclusions. In what follows, we present the justificatory conditions and offer 
suggestions on what would need to occur before a determination is made 
regarding whether any particular HIV vaccine should be licensed and approved 
for marketing. 
1. Effectiveness:  The policy must be expected to achieve its aim. 
HIV vaccines pose a challenge to this requirement: What level of real-
world effectiveness is sufficient? How long must it be sustained? Just as the 
FDA has issued Guidance for Industry: Clinical Data Needed to Support the 
Licensure of Pandemic Influenza Vaccines,215 it would be helpful if the FDA 
issued proactive guidance on the bounds of effectiveness that would be 
considered acceptable for licensing an HIV vaccine. Further research is also 
needed to provide reliable data on real-world effectiveness as opposed to 
efficacy within a controlled trial. 
2. Proportionality:  The good achieved must balance favorably against 
the infringement of other values. 
Determinations of proportionality require that the benefits of a vaccine be 
weighed against at least two competing considerations: cost and risk 
compensation. Between 2009 and 2013, worldwide R&D expenditures on an 
HIV vaccine were approximately $4.27 billion.216 Is an HIV vaccine likely to 
be cost-effective after considering anticipated real-world effectiveness rates, 
costs of implementing the program with boosters, and ongoing needs for 
education and treatment? And will the effectiveness rates be high enough to 
reduce the disease burden even after taking into account risk compensation? To 
answer this question, we urgently need updated mathematical models of the 
potential for risk compensation in the context of a vaccination campaign in the 
U.S. Proportionality determinations may vary significantly depending on the 
population in which the vaccine is approved for use. However, such a 
determination might rest largely upon answers to other questions posed 
(pertaining to effectiveness, cost, and risk compensation). 
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3. Necessity:  The infringement of values must be necessary to achieve 
the intended public health goal. 
One could argue that an HIV vaccine would likely pass this test because 
there is no way to develop an HIV vaccine that will not incur costs or run the 
risk of some risk compensation. However, one could also argue that it is not 
necessary to approve a vaccine with lower than standard rates of efficacy. That 
is, if the ultimate goal is to reduce the burden of HIV on the population using 
limited funds, one could argue that it makes more sense to focus funding on 
other prevention measures, treatment, and R&D aimed not only at vaccines, 
but also on treatments or cures. 
4. Least infringement:  The infringement of other values should be 
minimized. 
One obvious strategy for least infringement might be to initially approve 
an HIV vaccine only for high-risk populations and to approve the vaccine for a 
limited period of time, to conduct post-marketing research that might include 
cost-effectiveness and the impact on risk compensation. 
5. Public justification:  Policy makers should be transparent and explain 
the reasons for the policy. 
More generally, we would interpret this to require inclusion of 
stakeholders in deliberations, such as through public comment opportunities or 
the creation of review boards that reflect diversity. To satisfy this justificatory 
condition, two modifications of FDA processes might be appropriate. First, the 
FDA’s approval process requires an overall determination that the anticipated 
benefits outweigh risks.217 The scope of this risk-benefit analysis is not clearly 
articulated. Can it include the risk of diverting public funding from research on 
cures and the provision of treatments? Can it include risks of behavioral 
change? Clarifying the scope of the risk-benefit analysis prospectively and 
transparently will assist in the evaluation of an HIV licensing application. 
Second, the composition of FDA’s review committees might benefit from 
expansion to include diverse epidemiologists, policy experts, economists, 
ethicists, and representatives of populations most at risk for HIV infection. 
Within the FDA, the Center for Biologics Evaluation and Research (CBER) 
reviews applications for the approval of vaccines.218 A former director of 
CBER, Norman Taylor, states “[m]ost of our staff started in a laboratory or in 
 
 217. About FDA: How FDA Evaluates Regulated Products: Drugs, FOOD & DRUG ADMIN., 
http://www.fda.gov/AboutFDA/Transparency/Basics/ucm269834.htm (last visited March 3, 
2015). 
 218. Vaccine Product Approval Process, FOOD & DRUG ADMIN., http://www.fda.gov/biolog 
icsbloodvaccines/developmentapprovalprocess/biologicslicenseapplicationsblaprocess/ucm1330 
96.htm (last updated June 18, 2009). 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
258 SAINT LOUIS UNIVERSITY JOURNAL OF HEALTH LAW & POLICY [Vol. 8:225 
a clinical setting, a hospital or some other clinical setting, so we have . . . the 
ability and the knowledge base to evaluate these products.”219 However, it is 
unclear whether standard CBER laboratory and clinical backgrounds and data 
analysis are adequate to make the required determination of efficacy when 
efficacy is well below previously approved thresholds and diminishes rapidly 
in the absence of boosters (or perhaps even with boosters). It is even less clear 
that CBER staff have the expertise to conduct the kind of broad risk-benefit 
analysis described above. The FDA does have a standing Vaccines and Related 
Biological Products Advisory Committee (VRBPAC), which can provide a 
secondary review of applications. However, it is unclear whether the 
composition of the advisory committee reflects the broad array of expertise and 
stakeholder representation that the review of an HIV vaccine might require. 
Like most citizens of the world, we hope that science will one day produce 
an HIV vaccine that is similar to many other vaccines, with rates of efficacy 
approaching one hundred percent. In the meantime, health policy makers will 
do well to anticipate the opportunities and challenges that a moderately 
effective HIV vaccine will present. 
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